To accelerate the development of gene therapies for the 30 million Americans who have been diagnosed with a rare disease, in October 2021 the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), 10 pharmaceutical companies, and five nonprofit organizations announced the creation of the Bespoke Gene Therapy Consortium (BGTC)....
Latest News
London, UK – Cancer Research UK-funded scientists are finding out if an ingredient commonly found in grape juice and wine could keep bowel cancer at bay. Resveratrol – a naturally occurring ingredient found in grapes, blueberries, raspberries and peanuts – will be tested as a potential cancer prevention drug as...
SPRING HOUSE, Pa. — Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company’s innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025...
Basel, Switzerland – Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Annual Meeting in Barcelona, Spain, on September 24–26. Data from the ARTIOS Phase IIIb, open-label, single-arm,...
EAST HANOVER, N.J. — Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN). In the analysis, patients treated with Fabhalta achieved a 38.3% (p<0.0001) proteinuria reduction...
Okayama, Japan – Pancreatic cancer, recognized as one of the deadliest cancers, poses a persistent challenge for medical professionals globally due to its aggressive behavior and resistance to conventional therapies. The dense fibrotic tissue surrounding pancreatic tumors acts as a significant barrier, hindering the delivery of macromolecular drugs such as...
CHICAGO – New long-term findings from the Phase 3b study of patients with moderately to severely active Crohn’s disease having inadequate response to conventional therapies, but naive to immunomodulators and biologic therapy, were presented at Digestive Disease Week today. Data from the SONIC study showed that a greater proportion of...
Paris, France – Metachromatic leukodystrophy is a rare genetic disorder that affects between 1 and 9 people out of 100,000 and manifests itself mainly in childhood and adolescence—with 10 to 20% of cases observed in adulthood. The disease is hereditary but requires both parents to carry the mutated ARSA gene,...
Reston, VA — A novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of The Journal of Nuclear Medicine. The results of the study suggest that the agent 68Ga-DPI-4452 (Debio 0328) is superior...
Reston, VA — A novel imaging approach, 68Ga-pentixafor PET/CT, has been shown to accurately identify sub-types of primary aldosteronism (an adrenal gland disorder), outperforming traditional methods for diagnosis. Reported in the January issue of The Journal of Nuclear Medicine, this detailed imaging technique provides a clearer picture of the adrenal glands, helping...